Nuo Therapeutics, INC Form 4 insider transactions

Peter Clausen, CSO/COO of Nuo Therapeutics, Inc., received an option grant for 65,000 shares of common stock.

Nuo Therapeutics CEO David Emerson reports significant stock transactions, including option exercises and acquisitions, impacting his beneficial ownership.

Scott M. Pittman, a Director and 10% Owner of Nuo Therapeutics, Inc., reported transactions involving the acquisition and net exercise of stock options.

Nuo Therapeutics, Inc. Director C. Eric Winzer reports transactions involving common stock and stock options.

Nuo Therapeutics Director Paul Mintz acquired 30,000 stock options on June 29, 2026, as detailed in a Form 4 filing.

Nuo Therapeutics CEO and CFO David Jorden acquired 13,245 shares of common stock at a weighted average price of $1.0952.

Nuo Therapeutics has amended its loan agreement with Director Scott M. Pittman, resulting in the issuance and restatement of several warrant tranches.

Director Scott M. Pittman acquired warrants for 74,316 shares at $1.50 each, tied to a new corporate loan agreement.

Nuo Therapeutics Director and 10% owner Scott M. Pittman acquired various warrants to purchase common stock with an exercise price of $1.50 per share.

Nuo Therapeutics CEO and CFO David Jorden exercised options for 125,000 shares, increasing his direct beneficial ownership.

Nuo Therapeutics Director C. Eric Winzer exercised options to acquire 68,750 shares of common stock and subsequently disposed of 13,750 shares for tax purposes.

Nuo Therapeutics Director Paul Mintz exercised stock options for 50,000 shares, increasing his direct beneficial ownership to 108,294 shares.

Nuo Therapeutics Director Paul Mintz exercised options for 50,000 shares, resulting in a net acquisition of 40,909 common shares.

Nuo Therapeutics' CEO and CFO, David Emerson Jorden, sold 200,000 shares of common stock in a private transaction to facilitate a personal real estate deal.

Nuo Therapeutics director C. Eric Winzer completed a net exercise of stock options, acquiring 92,654 shares of common stock.

Nuo Therapeutics Director C. Eric Winzer exercised stock options, resulting in a net acquisition of 92,654 common shares.

A director at Nuo Therapeutics, Paul Mintz, exercised stock options for 87,500 shares and subsequently had 20,115 shares withheld for tax and exercise costs.

Nuo Therapeutics' CEO/CFO, David Emerson Jorden, exercised stock options for 192,710 shares, increasing his direct beneficial ownership.

Peter Clausen, Nuo Therapeutics' CSO/COO, exercised options to acquire 183,853 shares of common stock.

Scott M. Pittman, a Director and 10% owner of Nuo Therapeutics, Inc., acquired 3,946 shares of common stock at $1.50 per share, increasing his direct beneficial ownership to 5,400,000 shares.

Charles E. Sheedy, a Director and 10% owner of Nuo Therapeutics, Inc., reported the acquisition of 133,333 shares of common stock at $1.50 per share, increasing his direct beneficial ownership to over 11.5 million shares.

Scott M. Pittman, a director at Nuo Therapeutics, exercised stock options, increasing his holdings in the company.

Director Charles E. Sheedy reports the acquisition of 125,000 shares of Nuo Therapeutics, Inc. at $0.75 per share.

Director C Eric Winzer reports acquisition of options to purchase 40,000 shares of Nuo Therapeutics common stock.

Director Scott M. Pittman reports acquisition of options to purchase 40,000 shares of Nuo Therapeutics common stock.

Director Paul Mintz reports acquisition of options to purchase 25,000 shares of Nuo Therapeutics common stock.

Director Charles E. Sheedy reports the acquisition of 100,000 shares of Nuo Therapeutics, Inc. at $0.75 per share.

Peter Clausen, CSO/COO of Nuo Therapeutics, purchased 15,000 shares of common stock at $0.75 per share on May 20, 2024, as reported in a Form 4 filing.

Scott M. Pittman, a director and 10% owner of Nuo Therapeutics, Inc., purchased 135,000 shares of common stock at $0.75 per share on May 20, 2024, increasing his total holdings to 5,178,345 shares.